KDD68908
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
APX-005,APX-005-M,APX-005M, CAS: 2305607-45-6
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers., PMID:39907035
Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer., PMID:38181044
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better., PMID:37964379
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy., PMID:37535056
Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?, PMID:36260984
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial., PMID:35662283
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1., PMID:34140403
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study., PMID:33387490
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
